Abivax (NASDAQ:ABVX) Shares Gap Up – Time to Buy?

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $142.31, but opened at $147.00. Abivax shares last traded at $142.64, with a volume of 285,247 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Piper Sandler reaffirmed an “overweight” rating and set a $142.00 price target on shares of Abivax in a research report on Tuesday, December 16th. Truist Financial set a $140.00 target price on shares of Abivax in a report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. Barclays started coverage on shares of Abivax in a research note on Monday, October 13th. They issued an “overweight” rating and a $142.00 price objective on the stock. Finally, Citizens Jmp increased their target price on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.73.

Abivax Trading Down 1.5%

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The stock has a market capitalization of $10.78 billion, a PE ratio of -33.10 and a beta of 0.48. The business’s 50-day moving average is $115.46 and its two-hundred day moving average is $78.94.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Institutional Trading of Abivax

Several hedge funds have recently modified their holdings of ABVX. Bank of America Corp DE boosted its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Abivax by 46.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company’s stock worth $13,813,000 after purchasing an additional 696,626 shares in the last quarter. Allostery Investments LP boosted its position in shares of Abivax by 86.0% during the 1st quarter. Allostery Investments LP now owns 1,099,654 shares of the company’s stock worth $6,873,000 after purchasing an additional 508,401 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after purchasing an additional 56,235 shares during the period. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.